Philip Comp to Treatment Outcome
This is a "connection" page, showing publications Philip Comp has written about Treatment Outcome.
Connection Strength
0.089
-
A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: The Danaparoid Hip Arthroplasty Investigators Group. Orthopedics. 1998 Oct; 21(10):1123-8.
Score: 0.024
-
Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood. 1995 Jun 01; 85(11):3034-9.
Score: 0.019
-
Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost. 2007 Sep; 5(9):1854-61.
Score: 0.011
-
Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2005 Oct; 87(10):2169-77.
Score: 0.010
-
Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2005 May; 3(5):962-8.
Score: 0.009
-
Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003 Oct 30; 349(18):1703-12.
Score: 0.008
-
Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg. 2002 Mar-Apr; 36(2):83-91.
Score: 0.008